Jacob Sands, MD
Hematology & Oncology · Burlington, MANPI 1356491237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $261,950 of the $354,178 with a category attached, or 74.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.1%. 2025 is the largest year on record at $110,881, 3.3 times the $33,798 reported in 2019. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $1255.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$75K
- Daiichi Sankyo Inc.$43K
- Jazz Pharmaceuticals Inc.$40K
- Astrazeneca UK Limited$37K
- Amgen$31K
- Merck$24K
- plus $104K from 26 others
Across 631 payments — averaging $20,475 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$5.9M
- Daiichi Sankyo Company LTD$4M
- Eli Lilly$1.5M
- Amgen$642K
- Takeda Pharmaceuticals U.S.A., Inc.$244K
- Catalyst Pharmaceuticals, Inc.$199K
- plus $510K from 10 others
What the payments were for
- Consulting fees$261,95074%
- Speaking & faculty fees$59,84417%
- Travel & lodging$19,9576%
- Food & beverage$12,3273%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $74,833 |
| Daiichi Sankyo Inc. | 38 | $43,413 |
| Jazz Pharmaceuticals Inc. | 31 | $40,296 |
| Astrazeneca UK Limited | 16 | $36,853 |
| Amgen | 18 | $30,814 |
| Merck | 16 | $24,145 |
| Gilead | 15 | $15,282 |
| Boehringer Ingelheim International GmbH | 3 | $13,662 |
| Eli Lilly | 12 | $9,118 |
| Fosun Pharma USA Inc. | 9 | $8,610 |
| Astrazeneca AB | 9 | $8,286 |
| Pfizer | 9 | $7,576 |
| AbbVie | 6 | $5,995 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $5,445 |
| Genentech USA, Inc. | 4 | $4,762 |
| Foundation Medicine, Inc. | 4 | $4,744 |
| G1 Therapeutics, Inc. | 2 | $3,007 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| GSK | 1 | $2,400 |
| Sanofi | 1 | $2,312 |
| Blueprint Medicines Corporation | 1 | $2,256 |
| Genentech, Inc. | 2 | $1,933 |
| Bayer | 3 | $1,624 |
| Boehringer Ingelheim | 2 | $1,390 |
| F. Hoffmann-la Roche AG | 2 | $1,230 |
| Catalyst Pharmaceuticals, Inc. | 1 | $750 |
| Coherus Oncology, Inc. | 4 | $488 |
| Legend Biotech USA Inc. | 1 | $191 |
| Puma Biotechnology, Inc. | 1 | $175 |
| EMD Serono, Inc. | 2 | $101 |
| Tesaro, Inc. | 2 | $76 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$39,645
- IMFINZI$33,847
- IMDELLTRA (AMG 757)$20,685
- TAGRISSO$9,774
- Trodelvy$9,115
- DATROWAY$8,408
- GILOTRIF$6,952
- TECENTRIQ$5,740
- ALUNBRIG$5,445
- FOUNDATIONONE CDX$4,744
- FOUNDATIONACT$4,379
- FOUNDATIONFOCUS$4,379
- FOUNDATIONONE HEME$4,379
- FOUNDATIONONE$4,379
- LORBRENA$3,616
- Serplulimab$3,220
- COSELA$3,007
- Vitrakvi$1,500
- Alecensa$1,230
- FIRDAPSE$750
How this compares
$354,178 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 19 | $181 |
| Prochlorperazine Maleate | 12 | $148 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Burlington
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Stephanie BernsteinWinchester$622K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Karl DsilvaPeabody$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.